A Pilot Study to Evaluate Effectiveness of Botulinum Toxin in Treatment of Androgenetic Alopecia in Males

Sehdev Singh, Shekhar Neema, Biju Vasudevan, Sehdev Singh, Shekhar Neema, Biju Vasudevan

Abstract

Introduction: Androgenetic alopecia is a common form of alopecia with multifactorial etiology. Finasteride and minoxidil are approved by the FDA for the treatment of androgenetic alopecia. Balding scalp is believed to have relative microvascular insufficiency. Blood vessels in the scalp travel through the intramuscular plane. Intramuscular injection of botulinum toxin relaxes muscles and thereby increases blood flow in balding scalp. We conducted a pilot study to evaluate the efficacy of botulinum toxin in androgenetic alopecia management.

Material and methods: The study was conducted in a tertiary care center. A total of 10 male patients with androgenetic alopecia meeting inclusion criteria of the study were included. In the scalp, 30 sites were injected with 5 U of botulinum toxin in each site. Preprocedure photograph taken and evaluation was done, which was repeated after 24 weeks. Efficacy was assessed by photography and self-assessment scoring was done by patients.

Results: Of 10 patients, 8 had good to excellent response on photographic assessment. At the end of 24 weeks, 1 patient showed poor and 1 showed fair response to treatment. As per self-assessment, 7of 10 patients showed good to excellent response. Two patients had fair response and 1 patient showed poor response to treatment.

Conclusion: Botulinum toxin was found to be safe and effective therapy for the management of androgenetic alopecia in this pilot study. Studies with larger sample size and randomized controlled trials are required to establish the role of botulinum toxin in the management of androgenetic alopecia.

Keywords: Androgenetic alopecia; botulinum toxin; male pattern baldness.

Conflict of interest statement

None.

Figures

Figure 1
Figure 1
Sites for injections
Chart 1
Chart 1
Improvement as per photographic assessment at 24 weeks
Chart 2
Chart 2
Improvement as per patient at 24 weeks
Figure 2
Figure 2
(A and B) Excellent response seen at 24 weeks
Figure 3
Figure 3
(A and B) Excellent response seen at 24 weeks
Figure 4
Figure 4
(A and B) Good response seen at 24 weeks
Figure 5
Figure 5
(A and B) Fair response seen at 24 weeks
Figure 6
Figure 6
(A and B) Poor response seen at 24 weeks

References

    1. Tang PH, Chia HP, Cheong LL, Koh D. A community study of male androgenetic alopecia in Bishan, Singapore. Singapore Med J. 2000;41:202–5.
    1. Sehgal VN, Kak R, Aggarwal A, Srivastava G, Rajput P. Male pattern androgenetic alopecia in an Indian context: a perspective study. J Europ Acad Dermatol Venereol. 2007;21:473–9.
    1. Lad V, Suryawanshi C, Sinhal A, Landge A, Wagh V, Jadhav N. Androgenic alopecia: current perspectives & treatments. 2017;6(3):641–53.
    1. Rathnayake D, Sinclair R. Male androgenetic alopecia. Expert Opin Pharmacother. 2010;11:1295–304.
    1. Freund BJ, Schwartz M. Treatment of male pattern baldness with botulinum toxin: a pilot study. Plast Reconstr Surg. 2010;126:246e–8e.
    1. Orentreich N. Autografts in alopecias and other selected dermatological conditions. Ann N Y Acad Sci. 1959;83:463–79.
    1. Zappacosta AR. Reversal of baldness in patient receiving minoxidil for hypertension. N Engl J Med. 1980;303:1480–1.
    1. Goldman BE, Fisher DM, Ringler SL. Transcutaneous PO2 of the scalp in male pattern baldness: a new piece to the puzzle. Plast Reconstr Surg. 1996;97:1109–16.
    1. Dingman RO, Argenta LC. The surgical repair of traumatic defects of the scalp. Clin Plast Surg. 1982;9:131–44.
    1. Sansone-Bazzano GA, Reisner RM, Bazzano G. Conversion of testosterone-1, 23H to androstenedione-3H in the isolated hair follicle of man. J Clin Endocrinol Metabol. 1972;34:512–5.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir